1349 related articles for article (PubMed ID: 28052626)
1. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
2. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Banini BA; Sanyal AJ
Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
[TBL] [Abstract][Full Text] [Related]
3. Current treatment of non-alcoholic fatty liver disease.
Paternostro R; Trauner M
J Intern Med; 2022 Aug; 292(2):190-204. PubMed ID: 35796150
[TBL] [Abstract][Full Text] [Related]
4. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH.
Sobhia ME; Kumari S; Kumar H; Gandhe A; Kaushik D; Kumar H; Jain J; Ankita ; Mallick M; Pavani B; Moudgil M; Patel D
Curr Top Med Chem; 2023; 23(21):2027-2047. PubMed ID: 37455455
[TBL] [Abstract][Full Text] [Related]
6. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
7. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
Borrelli A; Bonelli P; Tuccillo FM; Goldfine ID; Evans JL; Buonaguro FM; Mancini A
Redox Biol; 2018 May; 15():467-479. PubMed ID: 29413959
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of contemporary drug clinical trials regarding the treatment of non-alcoholic steatohepatitis.
Zhao S; Zhang L; Zhao J; Kota VG; Venkat KM; Tasnim F; Yu H
Diabetes Metab Syndr; 2024 Jan; 18(1):102921. PubMed ID: 38128261
[TBL] [Abstract][Full Text] [Related]
9. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies.
Lee YA; Friedman SL
J Intern Med; 2022 Jan; 291(1):11-31. PubMed ID: 34564899
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease and Obesity Treatment.
Brunner KT; Henneberg CJ; Wilechansky RM; Long MT
Curr Obes Rep; 2019 Sep; 8(3):220-228. PubMed ID: 30945129
[TBL] [Abstract][Full Text] [Related]
12. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.
Oseini AM; Cole BK; Issa D; Feaver RE; Sanyal AJ
Hepatol Int; 2018 Jan; 12(1):6-16. PubMed ID: 29299759
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
[TBL] [Abstract][Full Text] [Related]
14. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
15. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.
Lindenmeyer CC; McCullough AJ
Clin Liver Dis; 2018 Feb; 22(1):11-21. PubMed ID: 29128051
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
[TBL] [Abstract][Full Text] [Related]
17. Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C; Fougerat A; Ellero-Simatos S; Loiseau N; Guillou H; Gamet-Payrastre L; Wahli W
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33371482
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).
Xu X; Poulsen KL; Wu L; Liu S; Miyata T; Song Q; Wei Q; Zhao C; Lin C; Yang J
Signal Transduct Target Ther; 2022 Aug; 7(1):287. PubMed ID: 35963848
[TBL] [Abstract][Full Text] [Related]
19. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Cells; ; . PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
